Ocular assessment of patients treated with tamoxifen.
Tamoxifen is a specific estrogen antagonist used in the treatment of breast cancer. In a previous study, corneal and retinal changes were reported in four patients receiving high-dose tamoxifen therapy for greater than 1 year. Nineteen patients treated with tamoxifen for periods of 3 months to 4 years at normal dose levels have been studied and no ocular changes attributable to the drug were observed.
D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D003315:Cornea / Q000187:drug effects; D005123:Eye / Q000187:drug effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D012160:Retina / Q000187:drug effects; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
D013629:Tamoxifen